Chief Medical Officer · Vor Biopharma Inc. (VOR)

Eyal Attar

A named executive officer of Vor Biopharma in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,075,785

Salary $487,100Stock awards $150,625

FY2023: $1,400,120

2nd of 3 named executive officers at Vor Biopharma by FY2024 total.

3 named officers on file for Vor Biopharma, FY2024

Eyal Attar’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vor Biopharma’s whole pay program stands against its peers

  • Vor Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VOR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 8, 2025 (DEF 14A).

Free

Get Eyal Attar’s full pay file as a PDF — free

More than this page: up to 10 years of Eyal’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Eyal Attar compensation by year

Vor Biopharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as Vor Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$474,000$487,100
Bonus$0$0
Stock awards$302,475$150,625
Option awards$437,090$230,000
Non-equity incentive$180,286$195,303
Pension and deferred compensation$0$0
All other$6,269$12,757
Total$1,400,120$1,075,785

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vor Biopharma Inc. DEF 14A filed April 8, 2025, accession 0001193125-25-075715, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vor Biopharma Inc. filed document, accession 0001193125-25-075715. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2025.

$1.4M
$1.1M
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU50,782$56,368—
RSU30,657$34,029—
Option59,042—$5.55
Option166,834—$3.77
Option98,959—$2.41

Per the Outstanding Equity Awards at Fiscal Year-End table in Vor Biopharma Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Vor Biopharma’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Robert AngFormer President and Chief Executive Officer$2,220,349
Eyal Attar · this pageChief Medical Officer$1,075,785
Tirtha ChakrabortyChief Scientific Officer and Head of Technical Operations$1,003,852

The full Vor Biopharma compensation record

free company brief

This page is one person within Vor Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vor Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Eyal Attar's compensation dossier · One-time report. No refunds.